Targeting of α νβ 3-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles

Nanomedicine

Volumn 5, Issue 5, 2010, Pages 715-726

  Akers, Walter J ^a   Zhang, Zongren ^a   Berezin, Mikhail ^a   Ye, Yunpeng ^a   Agee, Anthony ^a   Guo, Kevin ^a   Fuhrhop, Ralph W ^b   Wickline, Samuel A ^b   Lanza, Gregory M ^b   Achilefu, Samuel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

3 integrin; angiogenesis; cancer; emulsion; fluorescence; near infrared; optical imaging; peptide; perfluorocarbon

Indexed keywords

CONTRAST MEDIUM; CYCLOARGINYLGLYCYLASPARTIC ACID FLUOROKETONE; CYCLOPEPTIDE; CYPATE C 18; CYPATE CYCLOARGINYLGLYCYLASPARTIC ACID FLUOROKETONE CONJUGATE; DIAGNOSTIC AGENT; FLUORESCENT DYE; FLUOROCARBON; LIGAND; NANOPARTICLE; OCTADECYLAMINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CANCER TISSUE; COMPARATIVE STUDY; CONJUGATE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG FORMULATION; DRUG UPTAKE; ENDOTHELIUM CELL; FEMALE; FLUOROMETER; HIGH RESOLUTION OPTICAL IMAGING; IMAGING SYSTEM; ISOGRAFT; KIDNEY; LIVER; MALE; MOLECULAR IMAGING; MOLECULAR SIZE; NANOIMAGING; NEAR INFRARED SPECTROSCOPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; TUMOR CELL; TUMOR VASCULARIZATION; WHOLE BODY IMAGING;

ANIMALS; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; FLUORESCENT DYES; FLUOROCARBONS; HUMANS; INDOLES; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PEPTIDES, CYCLIC; SPECTROSCOPY, NEAR-INFRARED; WHOLE-BODY COUNTING;

EID: 77954915645     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.38     Document Type: Article

References (31)

1. Debbage P, Jaschke W: Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem. Cell Biol. 130(5), 845-875 (2008).
2. Kobayashi H, Lin PC: Nanotechnology for antiangiogenic cancer therapy. Nanomedicine (Lond.) 1(1), 17-22 (2006).
3. Meyer A, Auernheimer J, Modlinger A, Kessler H: Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12(22), 2723-2747 (2006).
4. Dijkgraaf I, Beer AJ, Wester HJ: Application of RGD-containing peptides as imaging probes for a expression. Front. Biosci. 14, 887-899 (2009).
5. Cai W, Chen X: Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49(Suppl. 2), 113S-128S (2008).
6. Kaufmann BA, Lindner JR: Molecular imaging with targeted contrast ultrasound. Curr. Opin. Biotechnol. 18(1), 11-16 (2007).
7. Ye Y, Li WP, Anderson CJ, Kao J, Nikiforovich GV, Achilefu S: Synthesis and characterization of a macrocyclic near- infrared optical scaffold. J. Am. Chem. Soc. 125(26), 7766-7767 (2003).
8. Ye Y, Bloch S, Xu B, Achilefu S: Design, synthesis, and evaluation of near infrared fluorescent multimeric rgd peptides for targeting tumors. J. Med. Chem. 49(7), 2268-2275 (2006).
9. Tran TD, Caruthers SD, Hughes M etal.: Clinical applications of perfluorocarbon nanoparticles formolecular imaging and targeted therapeutics. Int. J. Nanomedicine 2(4), 515-526
10. Neubauer AM, Sim H, Winter PM et al.: Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn. Reson. Med. 60(6), 1353-1361
11. Anderson SA, Rader RK, Westlin WF et al.: Magnetic resonance contrast enhancement of neovasculature with ap-targeted nanoparticles. Magn. Reson. Med. 44(3), 433-439 (2000).
12. Winter PM, Caruthers SD, Kassner A et at.: Molecular imaging of angiogenesis in nascent vx-2 rabbit tumors using a novel a^ p3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res. 63(18), 5838-5843 (2003).
13. Schmieder AH, Winter PM, Caruthers SD et al.: Molecular MR imaging of melanoma angiogenesis with avp3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 53(3), 621-627 (2005).
14. Hu G, Lijowski M, Zhang H et al.: Imaging of vx-2 rabbit tumors with a p3-integrin-targeted 111ln nanoparticles. Int. J. Cancer 120(9), 1951-1957 (2007).
15. Winter PM, Schmieder AH, Caruthers SD et al.: Minute dosages of aMp3-targeted fumagillin nanoparticles impair vx-2 tumor angiogenesis and development in rabbits. FASEBJ. 22(8), 2758-2767 (2008).
16. Schmieder AH, Caruthers SD, Zhang H et al.: Three-dimensional MR mapping of angiogenesis with a5p1(avp3)-targeted theranostic nanoparticles in the MDA- MB-435 xenograft mouse model. FASEB. J. 22(12), 4179-4189 (2008).
17. Lijowski M, Caruthers S, Hu G et al.: High sensitivity: high-resolution spect-CT/ MR molecular imaging of angiogenesis in the vx2 model. Invest. Radiol. 44(1), 15-22 (2009).
18. Edwards WB, Akers WJ, Ye Y et al.: Multimodal imaging of integrin receptor- positive tumors by bioluminescence, fluorescence, g scintigraphy, and single- photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol. Imaging 8(2), 101-110 (2009).
19. Winter PM, Neubauer AM, Caruthers SD et al.: Endothelial a, pintegrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.Arterioscler. Thromb. Vasc. Biol.26(9):2103-2109(2006)
20. Lakowicz JR: Principles of Fluorescence Spectroscopy. Springer, Berlin, Germany (2006).
21. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R: Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest. Radiol. 35(8), 479-485 (2000).
22. Meoli DF, Sadeghi MM, Krassilnikova S et al.: Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Invest. 113(12), 1684-1691 (2004).
23. Sadeghi MM, Krassilnikova S, Zhang J et al.: Detection of injury-induced vascular remodeling by targeting activated avp3 integrin in vivo. Circulation 110(1), 84-90 (2004).
24. Longmire M, Choyke PL, Kobayashi H: Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine (Lond.) 3 (5), 703-717 (2008).
25. Almutairi A, Akers WJ, Berezin MY, Achilefu S, Frechet JM: Monitoring the biodegradation of dendritic near-infrared nanoprobes by in vivo fluorescence imaging. Mol. Pharm. 5(6), 1103-1110 (2008).
26. Lanza GM, Yu X, Winter PM et al.: Targeted antiproliferative rug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106, 2842-2847 (2002).
27. Crowder KC, Hughes MS, Marsh JN et al.: Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery. Ultrasound Med. Biol. 31(12), 1693-1700 (2005).
28. Soman N, Lanza G, Heuser J, Schlesinger P, Wickline S: Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett. 8, 1131-1136 (2008).
29. Chen Y, Zheng G, Zhang ZH et al.: Metabolism-enhanced tumor localization by fluorescence imaging: in vivo animal studies. Opt. Lett. 28(21), 2070-2072 (2003).
30. Luker GD, Luker KE: Optical imaging: current applications and future directions. J. Nucl. Med. 49(1), 1-4 (2008).
31. Mulder WJ, Castermans K, Van Beijnum JR et al.: Molecular imaging of tumor angiogenesis using avp3-integrin targeted multimodal quantum dots. Angiogenesis 12(1), 17-24 (2009).